soul trial oral semaglutide cardiovascular outcomes results 2024 2025 Forecasting Milestones: A Predictive Analysis for Early Termination of the Study | Diabetes Therapy SOUL (Semaglutide cardiOvascular oUtcomes triaL)

Inhibition of GPR43/GPR109a expression by RNA interference Human G-protein-coupled receptor 43 (GPR43) or GPR109a siRNA or negative control (NC) siRNA was mixed with the Lipofectamine 2000 transfection reagent (Invitrogen, California, USA) (Table S1)

GLP-1

If there are no side effects and that dose is effective, continue with that strength and dose

Medical Review Author: Karla K

Common Side Effects (Both Oral and Injectable): Gastrointestinal Issues: These are the most common side effects for all GLP-1 medications: Nausea: Oral semaglutide (Rybelsus): 11-20% of patients Injectable semaglutide (Wegovy): 44% of patients Injectable tirzepatide (Zepbound): 30-37% of patients Why the difference: Lower bioavailability of oral medication means less systemic exposure, potentially resulting in fewer GI side effects

A: Cloudiness can indicate bacterial contamination, degradation from improper storage, or incomplete dissolution